Komori
Other Disclosures4918IVY COSMETICS CORPORATIONMaterials and Chemicals

Notice of Research Presentations at the 146th Annual Meeting of the Pharmaceutical Society of Japan (1)

At the 146th Annual Meeting of the Pharmaceutical Society of Japan, the company presented joint research on improving dark spots and treating skin diseases by utilizing interactions between melanocytes and macrophages, as well as nanocarriers for efficiently delivering active ingredients.

Worth reading
44Recurring
Scored from 5 of 6 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Applicable field (uses covered by this announcement)
CosmeticsQuasi-drugsImprovement of dark spots in pharmaceuticalsTreatment of melasma and ADMDevelopment of novel treatments for skin diseases, including melanoma
Launch date27–29 March 2026 (dates and results of the research presentations)
Relationship between the counterparty and the company
IVY COSMETICS CORPORATION4918
Relationship with the Company

Joint Research

CounterpartyKeio University Graduate School of Science and TechnologyKogakuin University Faculty of Advanced EngineeringYamaguchi University Graduate School of MedicineDoshisha University Faculty of Life and Medical Sciences
Impact on Business Performance

At present, there is no impact on results for the current fiscal year.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

146th Annual Meeting of the Pharmaceutical Society of Japan

Announced details
ItemDetails
CounterpartyKeio University Graduate School of Science and Technology, Kogakuin University Faculty of Advanced Engineering, Yamaguchi University Graduate School of Medicine, Doshisha University Faculty of Life and Medical Sciences
Relationship with the CompanyJoint Research
Launch date27–29 March 2026 (dates and results of the research presentations)
Applicable areaCosmetics, Quasi-drugs, Improvement of dark spots in pharmaceuticals, Treatment of melasma and ADM, Development of novel treatments for skin diseases, including melanoma
Impact on Business PerformanceAt present, there is no impact on results for the current fiscal year.
Source146th Annual Meeting of the Pharmaceutical Society of Japan
Items this document does not state (12)
Names of Products / Services CoveredCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explains that there is currently no impact on results for the current fiscal year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Research Presentations at the 146th Annual Meeting of the Pharmaceutical Society of Japan (1) | IVY COSMETICS CORPORATION (4918) timely disclosure | Komori